Načítá se...
A Novel Hydrogen Sulfide Prodrug, SG1002, Promotes Hydrogen Sulfide and Nitric Oxide Bioavailability in Heart Failure Patients
Recent studies demonstrate robust molecular cross talk and signaling between hydrogen sulfide (H(2)S) and nitric oxide (NO). Heart failure (HF) patients are deficient in both H(2)S and NO, two molecules that are critical for cardiovascular homeostasis. A phase I clinical trial of a novel H(2)S prodr...
Uloženo v:
| Vydáno v: | Cardiovasc Ther |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5034803/ https://ncbi.nlm.nih.gov/pubmed/25930144 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1755-5922.12128 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|